Enhancing the affinity of novel GLS1 allosteric inhibitors by targeting key residue Lys320
Aim: A series of novel GLS1 irreversible allosteric inhibitors targeting Lys320 might have robust enzyme inhibitory activity and potent antitumor activity. Materials & methods: Novel GLS1 allosteric inhibitors targeting Lys320 were synthesized and their anticancer activity was assessed. Moreover, GLS1 protein was used as a model system to analyze the reactivity of these electrophilic groups in GLS1 irreversible allosteric inhibitors with other amino acids, including tyrosine, histidine, serine and threonine, using biochemical and biophysical assays. Results: AC16 exhibited robust GLS1 inhibitory activity, antiproliferative effect in vitro, good plasma stability and potential covalent addition with GLS1 K320. Conclusion: This study opens a novel avenue for the design of robust irreversible GLS1 inhibitors targeting the allosteric site K320.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 15(2023), 15 vom: 07. Aug., Seite 1393-1414 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Li [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allosteric |
|---|
| Anmerkungen: |
Date Revised 10.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.4155/fmc-2023-0114 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361092962 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361092962 | ||
| 003 | DE-627 | ||
| 005 | 20231226084419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2023-0114 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM361092962 | ||
| 035 | |a (NLM)37610850 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancing the affinity of novel GLS1 allosteric inhibitors by targeting key residue Lys320 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Aim: A series of novel GLS1 irreversible allosteric inhibitors targeting Lys320 might have robust enzyme inhibitory activity and potent antitumor activity. Materials & methods: Novel GLS1 allosteric inhibitors targeting Lys320 were synthesized and their anticancer activity was assessed. Moreover, GLS1 protein was used as a model system to analyze the reactivity of these electrophilic groups in GLS1 irreversible allosteric inhibitors with other amino acids, including tyrosine, histidine, serine and threonine, using biochemical and biophysical assays. Results: AC16 exhibited robust GLS1 inhibitory activity, antiproliferative effect in vitro, good plasma stability and potential covalent addition with GLS1 K320. Conclusion: This study opens a novel avenue for the design of robust irreversible GLS1 inhibitors targeting the allosteric site K320 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a GLS1 | |
| 650 | 4 | |a allosteric | |
| 650 | 4 | |a glutamine metabolism | |
| 650 | 4 | |a irreversible | |
| 650 | 4 | |a lysine | |
| 700 | 1 | |a Chang, Xiujin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shengpeng |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Xiumei |e verfasserin |4 aut | |
| 700 | 1 | |a Finko, Alexander V |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, Jinlei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Huidan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 15(2023), 15 vom: 07. Aug., Seite 1393-1414 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:15 |g day:07 |g month:08 |g pages:1393-1414 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2023-0114 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 15 |b 07 |c 08 |h 1393-1414 | ||